UNSPSC 51141551: Ciprazafone

This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8RSD11181G. European Medicines Agency schedules Ciprazafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07466MIG. Ciprazafone generally arises in the molecular formula C19H18CL2N2O2. The term CIPRAZAFONE is an International Non-Proprietary Name or INN. CIPRAZAFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule ciprazafone under HS 29242995 and SITC 51479. As of Q4 2014, CIPRAZAFONE remains the US FDA Preferred Term for this commodity. Ciprazafone bears US NLM identifiers UMLS ID C2699233 and NCI Concept Code C78000. SMILES: CLC1CC(C(N(C(=O)CNC2CC2)C)CC1)C(=O)C1C(CL)CCCC1.

UNSPSC 51141551 Ciprazafone is a Commodity code. State and local governments procuring under this code are actually buying pharmaceutical products and related health systems — most recently, naloxone (an opioid overdose antidote), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through cooperative purchasing arrangements and direct health agency procurement. The issuing bodies span county public health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida, posted an IFB for naloxone and drug deactivation systems in June 2026 (response deadline July 26, 2023); the Texas Health and Human Services Commission issued an RFI in April 2026 regarding direct-to-manufacturer pharmacy prescriptions; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026, for performance across Minnesota and Oregon.

Geographic activity centers on Florida, Texas, and Minnesota-Oregon, with MMCAP's cooperative vehicle extending across multiple states. The Seminole County solicitation supports community health initiatives with quarterly deliveries; the Texas RFI seeks vendor capacity for direct contracting with self-insured employee group health plans and state agencies outside traditional pharmacy benefit managers and group purchasing organizations; and the MMCAP RFP establishes multiple contracts for distribution through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with products required to be available by May 15, 2026, and contracts effective July 1, 2026. MMCAP's evaluation weights price competitiveness at 75 percent, with fixed pricing, administrative fee compliance, EDI capability, and fee acknowledgment collectively weighting 25 percent. No specific set-aside designations appear in the recent solicitations.